1692.0000 -33.20 (-1.92%)
NSE Aug 11, 2025 11:21 AM
Volume: 93,701
 

1692.00
-1.92%
Systematix Group
Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders: Eris has Develop, Manufacture and Commercialize branded prescription based pharmaceuticals products in select chronic and acute therapeutic areas, like Cardiovascular, Anti-Diabetics, Vitamins, Gastroenterology, Anti-Infectives, & Gynaecology. In FY17, they generated 65.6% of their revenues from the chronic category of the IPM. The chronic category accounted for 34.3% of the IPM in FY17 compared to 31.4% of the IPM in FY13, representing growth at a CAGR of 14.3%. They have identified, developed and are marketing products in the acute category, which are connected to...
Eris Lifesciences Ltd. is trading above its 200 day SMA of 1450.0
More from Eris Lifesciences Ltd.
Recommended